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Single dose combination nanovaccine provides protection against
influenza A virus in young and aged mice
Abstract
Immunosenescence poses a formidable challenge in designing effective influenza vaccines for aging
populations. While approved vaccines against influenza viruses exist, their efficacy in older adults is
significantly decreased due to the diminished capabilities of innate and adaptive immune responses. In this
work, the ability of a combination nanovaccine containing both recombinant hemagglutinin and
nucleoprotein to provide protection against seasonal influenza virus infection was examined in young and
aged mice. Vaccine formulations combining two nanoadjuvants, polyanhydride nanoparticles and pentablock
copolymer micelles, were shown to enhance protection against challenge compared to each adjuvant alone in
young mice. Nanoparticles were shown to enhance in vitro activation of dendritic cells isolated from aged
mice, while both nanoadjuvants did not induce proinflammatory cytokine secretion which may be
detrimental in aged individuals. In addition, the combination nanovaccine platform was shown to induce
demonstrable antibody titers in both young and aged mice that correlated with the maintenance of body
weight post-challenge. Collectively, these data demonstrate that the combination nanovaccine platform is a
promising technology for influenza vaccines for older adults.
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Single dose combination nanovaccine provides protection against 
influenza A virus in young and aged mice
Kathleen Ross,*a,f Sujata Senapati,*a Jessica Alley,b Ross Darling,c Jonathan Goodman,a Matthew 
Jefferson,d Metin Uz,a Baoqing Guo,e Kyoung-Jin Yoon,e David Verhoeven,c,f Marian Kohut,b,f Surya 
Mallapragada,a,f Michael Wannemuehler,c,f and Balaji Narasimhan †a,f
Immunosenescence poses a formidable challenge in designing effective influenza vaccines for aging populations. While 
approved vaccines against influenza viruses exist, their efficacy in older adults is significantly decreased due to the 
diminished capabilities of innate and adaptive immune responses. In this work, the ability of a combination nanovaccine 
containing both recombinant hemagglutinin and nucleoprotein to provide protection against seasonal influenza virus 
infection was examined in young and aged mice. Vaccine formulations combining two nanoadjuvants, polyanhydride 
nanoparticles and pentablock copolymer micelles, were shown to enhance protection against challenge compared to each 
adjuvant alone in young mice. Nanoparticles were shown to enhance in vitro activation of dendritic cells isolated from 
aged mice, while both nanoadjuvants did not induce proinflammatory cytokine secretion which may be detrimental in 
aged individuals. In addition, the combination nanovaccine platform was shown to induce demonstrable antibody titers in 
both young and aged mice that correlated with the maintenance of body weight post-challenge. Collectively, these data 
demonstrate that the combination nanovaccine platform is a promising technology for influenza vaccines for older adults.
Introduction
Influenza A virus (IAV) is a significant health threat to elderly 
populations, with up to 90% of influenza-related deaths 
occurring in patients 65 years and older.1 In addition, 
hospitalization rates due to influenza are two-fold higher in 
older adults and account for approximately $10.4 billion in U.S. 
medical costs each year.2, 3 Although the use of existing 
influenza vaccines may provide protection, these vaccines 
often have significantly lower efficacy and/or significant 
variability with respect to their performance in aged 
individuals.1, 4 For example, older adults were particularly 
affected during the 2017-2018 influenza season (which had a 
high severity of 48.8 million cases in the U.S.), by accounting 
for 70% of influenza-associated hospitalizations and 90% of 
influenza-related deaths.5
In light of these major public health challenges, it is 
important to understand the changes in aging-related immune 
functions and use this information to design new and 
improved vaccines for older adults. Immunosenescence, the 
decline in immune function with age, constitutes defects in 
both innate and adaptive immunity.6 These defects include the 
decline in haematopoietic stem cell function,7 decreased B cell 
numbers,8 reduced phagocytic ability of neutrophils,9 reduced 
expression of transcription factors,10 and thymic involution.11 
In addition, “inflamm-aging” is another consequence of 
immunosenescence, leading to the presence of an increased 
basal intrinsic inflammation in the immune system.12, 13 All of 
these age-related immune deficiencies often lead to poor 
antibody production (which typically doesn’t correlate with 
protection in older adults) and T cell responses post-
vaccination.14 Although recent studies have sought to improve 
responses in older adults through multiple or high dose 
immunizations,15, 16 there is an urgent need to improve 
vaccines for older adults.5 Thus, novel vaccine technologies 
may be required to induce protection against influenza in older 
adults.
Nanovaccines composed of polyanhydride nanoparticles 
and pentablock copolymers represent a novel platform for the 
design of subunit influenza vaccines. In particular, 
polyanhydride nanoparticles have been demonstrated to 
provide sustained release of encapsulated influenza antigens 
while enhancing antigen stability.17 In addition, polyanhydride-
based nanovaccines have been shown to induce anti-
hemagglutinin (HA) antibody titers capable of neutralizing 
influenza virus, inducing antigen-specific CD4+ and CD8+ T cell 
responses, including lung-resident memory phenotypes18 and 
providing protection against challenge.4 Similarly, pentablock 
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copolymers based on Pluronic F127 and polydiethylaminoethyl 
methacrylate (PDEAEM) represent another effective platform 
for affording sustained release of antigen, depositing the 
antigen in the cytosol, and promoting the rapid development 
of antibody titers.19, 20 Our previous work has shown that 
combination nanovaccines consisting of both polyanhydride 
nanoparticles and pentablock copolymers provided the 
greatest protection against influenza in young mice compared 
to either nanoadjuvant alone.21 That being said, older adults 
often require vaccines which stimulate the immune system 
without exacerbating the already inflamed state.22 Cyclic 
dinucleotides (CDNs), which are STING activators, have been 
previously shown to rapidly induce antibody titers in aged 
mice, without displaying the inflammatory profile of traditional 
TLR agonist adjuvants.23 In addition, CDN stimulation of 
dendritic cells has been shown to induce greater amounts of B 
cell activating factor (BAFF), which is important for germinal 
center maintenance and B cell survival.24, 25 
Herein, we describe the formulation of a combination 
nanovaccine based on these two nanoadjuvants, incorporating 
the hemagglutinin (HA) and nucleoprotein (NP) antigens from 
H1N1 IAV, and demonstrate the ability of the combination 
nanovaccine to provide protection against seasonal influenza 
virus. These nanovaccines enhanced dendritic cell activation, 
while limiting detrimental inflammation. Additionally, the 
combination nanovaccine combined with CDNs induced 
measurable anti-HA antibody titers in aged animals and limited 
weight loss post-challenge. Furthermore, the data 
demonstrated that a single dose of the combination 
nanovaccine was shown to provide protection against 
influenza virus in both young and aged animals. Collectively, 
the data presented here demonstrates the ability of the 
combination nanovaccine to reduce clinical disease following 
IAV infection in aged animals.
Experimental
Polyanhydride nanoparticle synthesis
Monomers of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) were 
synthesized as previously described.26, 27 Next, 20:80 
CPTEG:CPH polymer was synthesized via melt 
polycondensation.27 The resulting molecular weight (5,957 
g/mol), composition (24:76), and purity of the polymer were 
characterized with 1H nuclear magnetic resonance 
spectroscopy (1H NMR; DXR 500, Bruker, Billerica, MA).
Nanoparticles containing 1 wt. % H1 hemagglutinin (HA) 
and 1 wt. % nucleoprotein (NP) were synthesized using a solid-
oil-oil double emulsion technique as previously described.28 
Briefly, HA and NP proteins obtained from Sino Biological 
(Beijing, China) were dialyzed to nanopure water and 
lyophilized overnight. Next, 20 mg/mL of 20:80 CPTEG:CPH 
polymer containing 1 wt. % of each HA and NP was dissolved in 
methylene chloride. The solution was sonicated for 30 s to 
ensure that the polymer was dissolved and the protein evenly 
distributed. The solution was then poured into chilled pentane 
(-10°C; 1:250 methylene chloride:pentane) and the resulting 
particles collected via vacuum filtration. Nanoparticle 
morphology and size (~200 nm) were verified with scanning 
electron microscopy (FEI Quanta 250, FEI, Hillsboro, OR).
Pentablock copolymer micelle synthesis
A novel pentablock copolymer (PDEAEM-POE-POP-POE-
PDEAEM) was synthesized by atom transfer radical 
polymerization.29 A difunctional macroinitiator prepared from 
commercially available Pluronic®-F127 was dissolved in 
tetrahydrofuran and reacted overnight with triethylamine and 
2-bromoisobutyryl. The product was precipitated in n-hexane 
and characterized using 1H NMR to confirm the end group 
functionalization. Next, the macroinitiator and the DEAEM 
monomer were used to synthesize the pentablock copolymer 
utilizing copper (I) oxide nanoparticles as the catalyst and N-
propylpyrilidine methanamine as the complexing ligand.30 The 
pentablock copolymer was characterized with 1H NMR to 
determine purity and molecular weight (14,600 g/mol).
To formulate the micelles used in Fig. 1, a stock solution of 
30% poly(vinyl alcohol) (PVA; 10 kDa) was prepared in 
phosphate buffer saline (PBS) and added to a chilled solution 
of the pentablock copolymer (4.1 wt. %) and Pluronic® F-127 
(5.9 wt. %). Additional PBS containing HA, NP, and/or 
nanoparticles was added to the micelles resulting in a total of 
25 wt. % polymer. The suspension was then sonicated for 30 s 
to ensure even distribution of the protein and/or nanoparticles 
throughout the micelle solution used. In order to improve 
injectability of the formulation, later experiments (Fig. 2-7) 
utilized a reduced concentration of polymer. The final 
formulation was prepared similarly with 7.5 wt. % PVA, 2.95 
wt. % Pluronic® F-127 and 2.05 wt. % pentablock copolymer.
Inactivated virus
Influenza A/Puerto Rico/8/34 (H1N1) virus was purified from 
infected chicken embryo allantoic fluid. A sterile petri dish 
containing 2 mL of allantoic fluid (40,960 HAU/mL) was placed 
within 12 inches of a UV light inside a biosafety cabinet for 30 
min. After inactivation, no evidence of infectious virus was 
found based on a MDCK plaque assay. UV-inactivated virus 
was frozen at -80°C until 1 h prior to immunizations, at which 
point the UV-inactivated virus was thawed at room 
temperature, diluted 1:2.5 in physiological saline, and kept on 
ice until administration.
Mice
Female (6-8 week old) BALB/c mice were purchased from 
Charles River Laboratories (Wilmington, MA). Aged (~18 mo) 
mice were obtained from the National Institute of Aging 
(Bethesda, MD) or Charles River. All mice were housed under 
specific pathogen-free conditions where all bedding, caging, 
water, and feed were sterilized before use. All animal 
procedures were performed in accordance with the Guidelines 
for Care and Use of Laboratory Animals of Iowa State 
University and approved by the Iowa State University 
Institutional Animal Care and Use Committee.
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Immunizations
All mice were immunized subcutaneously with a total of 20 µg 
HA and 20 µg NP. In experiments using a two dose regimen 
(Fig. 1, 2, and 4), mice were immunized twice (day 0 and 21) 
with the following: Saline, Soluble (10 µg HA + 10 µg NP in 
PBS), Nanoparticle (5 µg HA + 5 µg NP encapsulated in 500 µg 
nanoparticles co-delivered with 5 µg HA + 5 µg NP in PBS), 
Micelle (10 µg HA + 10 µg NP in 100 µL of micelles), and 
Combination Nanoadjuvants (5 µg HA + 5 µg NP encapsulated 
in 500 µg nanoparticles co-delivered with 5 µg HA + 5 µg NP in 
100 µL of micelles). In experiments using a single dose regimen 
(Fig. 2-4) mice were administered the following: Combination 
Nanovaccine (5 µg HA + 5 µg NP encapsulated in 500 µg 
nanoparticles co-delivered with 15 µg HA + 15 µg NP in 100 µL 
of micelles), inactivated virus (50 µL containing 819 HAU 
administered intramuscularly into the rear flank), or saline. In 
the study demonstrating vaccine efficacy in aged mice (Fig. 7), 
5 µg of cyclic dinucleotides (CDNs; dithio-RP,RP-cyclic di-
guanosine monophosphate) provided by Aduro Biotech 
(Berkeley, CA) were included in the combination nanovaccine.
Antibody titers
Antibody titers were determined using an enzyme-linked 
immunosorbent assay (ELISA). First, 100 µL of blood was 
isolated from the saphenous vein of each mouse and 
centrifuged for 10 min at 10,000 x g. The serum was separated 
and stored at 4°C until further analysis. High binding, flat-
bottomed 96 well plates were coated with 100 µL/well of 0.5 
µg/mL HA or NP protein in PBS. After incubating overnight at 
4°C, the wells were emptied and blocked for 2 h at room 
temperature with 2% (w/v) gelatin in PBS with 0.05% Tween 
(PBS-T). Next, the plates were washed three times with PBS-T 
before adding 100 µL/well of PBS-T + 1% goat serum. Serum 
samples from immunized mice were added to each well 
beginning with a 1:200 dilution and performing 1:2 serial 
dilutions across the plate. After incubating overnight at 4°C, 
the plates were washed three times with PBS-T and incubated 
for 2 h at room temperature with 100 µL/well of 1:1000 
Alkaline Phosphatase-conjugated anti-mouse IgG H&L (Jackson 
ImmunoResearch, West Grove, PA). The plates were again 
washed with PBS-T before adding 100 µL/well of substrate 
buffer (50 mM sodium carbonate, 2 mM magnesium chloride, 
pH 9.3) containing 1 mg/mL p-nitrophenylphosphate (Fisher 
Scientific, Pittsburgh, PA). The optical density (405 nm) was 
recorded after 30 min. Titer was defined as the reciprocal of 
the last serum dilution that produced an optical density 
greater than twice the value of background (i.e., average 
optical density of saline administered mice).
Virus microneutralization
Serum samples were diluted 1:3 with receptor destroying 
enzyme (RDE; Denka Seiken, Tokyo, Japan) diluted according 
to the manufacturer’s instructions and incubated in a water 
bath at 37°C overnight. Next, the samples were heat 
inactivated by incubating in a water bath at 56°C for 1 h before 
adding media (DMEM with 1% Pen/Strep, Invitrogen, Carlsbad, 
CA) to bring the final serum dilution to 1:20. The serum 
samples (25 µL/well) were subsequently added to 96 well, 
round bottom plates in duplicate and 1:2 serial dilutions were 
performed down each column. Next, 25 µL of virus stock 
(A/PR/8/34; 2,000 TCID50/mL) were added to each well. After 
incubating for 1 h at 37°C, the samples were transferred to 96 
well plates seeded with 90% confluent Madin-Darby Canine 
Kidney (MDCK; BEI Resources, Manassas, VA) cells. The cells 
were incubated for 1 h at 37°C before washing with HBSS 
(Invitrogen) and adding 100 µL media supplemented with 10% 
FBS and 1 µg/mL TPK-trypsin (Fisher Scientific, Waltham, MA). 
After three days of incubation (37°C, 5% CO2), 50 µL of each 
well was transferred to a 96 well, V-bottom plate. Next, 50 µL 
of 0.75% turkey red bloods cells (Lampire, Hershey, PA) in 
HBSS was added to each well. The plates were incubated at 
room temperature for 45 min before reading the plates. The 
microneutralization titer was taken to be the last dilution of 
serum with the appearance of a button.
Virus challenge
Original influenza virus stocks (A/PR/8/34) were obtained from 
the Influenza Division of the Center for Disease Control and 
Prevention. The virus was propagated in the allantoic cavity of 
embryonated hen’s eggs, harvested after three days, and 
purified using a discontinuous sucrose gradient. The biological 
activity was determined using a hemagglutination assay and 
diluted to 10 HAU/mL before administering to mice. In the 
final experiment observing the vaccine efficacy of combination 
nanovaccines in aged mice, the virus stock was diluted to 100 
HAU/mL before administering to mice.
Mice were challenged intranasally with live virus 35-42 
days following the first immunization. Briefly, mice were 
anesthetized in a chamber with 3% isoflurane in 100% O2 at a 
flow rate of 2.5 L/min. Next, 50 µL of the prepared virus was 
pipetted onto the nares of the nose before recovering from 
anesthesia. All mice were monitored twice daily after 
challenge with body weight collected once per day. Animals 
were removed from study after losing greater than 25% their 
original body weight. A subset of mice was euthanized three 
days post-challenge for bronchoalveolar lavage (BAL) and lung 
tissue. The total IgG anti-HA antibody titer was determined 
using ELISA as described above. The lung tissue was used to 
determine virus load.
Virus load
Lung tissue was extracted and homogenized before 
quantitative reverse-transcription polymer chain reaction 
(qRT-PCR). A commercially available one-step real-time 
multiplex RT-PCR kit (VetMAX™-Gold SIV Detection Kit; Life 
Technologies, Austin, TX), designed to target viral matrix and 
nucleoprotein genes, was used to amplify influenza viral RNA. 
The PCR reaction was set up in a 25 µL volume containing 12.5 
µL of 2X multiplex RT-PCR buffer, 1.0 µL nuclease-free water, 
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1.0 µL of influenza virus primer probe mix, 2.5 µL of multiplex 
RT-PCR enzyme mix and 8.0 µL of RNA template (i.e., extract) 
or controls. Xeno™ RNA Control supplied with the kit was 
included as an internal control for RNA purity to assess 
possible PCR inhibition from samples. Influenza Virus-Xeno™ 
RNA Control (1000 copies/µL) included in the kit was used as a 
positive amplification control (PAC). Nuclease-free water was 
used as a no amplification control. Thermocycling was 
performed in a 7500 Fast PCR System (Applied Biosystems, 
Foster City, CA) under the following conditions: reverse 
transcription at 48°C for 10 min, reverse transcriptase 
inactivation/initial denaturation at 95°C for 10 min, and 40 
cycles of amplification and extension (95°C for 15 s and 60°C 
for 45 s).  
Samples with cycle threshold (Ct) values < 38 were 
recorded as positive for influenza A viral RNA, whereas 
samples with Ct values > 38 were recorded as negative as per 
manufacturer’s instructions. However, the data were collected 
until the end of run (40 cycles) and viral titers (TCID50/mL) 
appearing after the cut-off were included in the final statistical 
data analyses.
Characterization of aged dendritic cell response in vitro
Spleens from aged mice were collected after euthanasia 
following IACUC protocols. Single cell suspensions of spleen 
cells were isolated after treatment with Collagenase D and 
mechanical grinding of the spleens with RPMI media. A pan 
dendritic cells (DCs) negative selection kit (Miltenyi Biotech, 
Bergisch Gladbach, Germany) was used to isolate CD11c+ DCs 
from the total spleen cells using the manufacturer’s protocol. 
Briefly, the spleen cells were incubated with the antibody 
cocktail and magnetic microbeads provided in the kit and run 
through AutoMACS ProSeparator (Miltenyi Biotech) to collect 
the negative selection pool of CD11c+ DCs. Following isolation, 
2.5x106 - 5x106 spleen DCs were stimulated for 48 h with the 
following treatment groups: nanoparticles (500 μg/mL), 
micelles (12.5 μg/mL), LPS (1 μg/mL) and unstimulated control 
with or without a soluble model antigen (ovalbumin; sOva, 20 
μg/mL).
Following stimulation, the upregulation of costimulatory 
molecules were evaluated using flow cytometry. DCs were 
stained with antibodies for different co-stimulatory molecules, 
namely, CD80 (Biolegend, PerCP-Cy5.5, clone 16-10A1), CD11c 
(Biolegend, APC-Cy7, clone N418), MHCII (eBioscience, AF700, 
clone M5/114.15.2), CD86 (eBioscience, FITC, clone GL1) and 
CD40 (eBioscience, APC, clone 1C10). The cells were blocked 
prior to labelling by using 100 μg/mL of rat IgG (Sigma Aldrich) 
and 10 μg/mL of anti-CD16/32 (eBioscience). Supernatants 
from the splenic DCs stimulated with different treatment 
groups were collected and analyzed for the presence of 
cytokines and chemokines using MILLIPLEX® MAP mouse 
cytokine/chemokine magnetic bead panel (Millipore Sigma, 
Burlington, MA) on a Bio-Plex 200 system (Bio-Rad, Hercules, 
CA).
Statistics
Statistical significance (p ≤ 0.05) among treatments was 
determined using GraphPad (Prism 7.00, GraphPad Software, 
La Jolla, CA). Briefly, the Kruskal-Wallis and Mann-Whitney 
tests were used to compare vaccine formulations in all 
antibody or virus load data. A repeated measures ANOVA was 
used to determine significance of weight loss post-challenge. 
The log rank Mantel-Cox test determined significance of 
survival data. Finally, statistical significance among treatment 
groups in dendritic cell experiments was determined using a 
Tukey T-test.
Results
Nanoadjuvants enhanced immune response post-vaccination
To assess the combination of nanoadjuvants (i.e., 
nanoparticles and micelles), young (6-8 wk old) BALB/c mice 
were subcutaneously immunized twice (day 0 and 21) with 
each dose containing 10 µg of recombinant HA and 10 µg of 
recombinant NP derived from A/PR/8/34 virus. Serum samples 
were collected 35 days after the first immunization and 
analyzed for anti-HA antibody titers. As shown in Fig. 1A, all 
nanoadjuvanted formulations induced significantly greater 
antibody titers in comparison to soluble antigen alone. In 
addition, mice receiving formulations containing the 
pentablock copolymer micelles demonstrated the greatest 
mean antibody titers.
At 42 days post-immunization, the mice were intranasally 
challenged with live A/PR/8/34 virus. Three days post-
challenge, six mice within each group were euthanized and 
their lung viral load was quantified. The lungs of mice 
administered the nanoadjuvant formulations showed a 
significant reduction in viral load, with the lungs of animals 
administered the combination nanoadjuvant showing a seven-
log reduction in mean viral load compared to mice 
administered soluble antigen (Fig. 1B). Furthermore, no virus 
was detected in most of the mice (5/6) receiving the 
combination nanoadjuvant formulation at three days post-
challenge compared to mice administered nanoparticle (2/6) 
or micelle (4/6) formulations alone. 
Finally, the remaining mice were weighed daily for eight 
days post-challenge. The saline-administered mice began to 
lose weight three days post-challenge, and continued to lose 
up to 20% their original body weight (Fig. 1C). In contrast, all 
vaccinated mice maintained their body weight post-infection 
regardless of nanoadjuvant formulation used and were 
significantly different compared to saline controls.
Assessing the efficacy of a single dose vaccine regimen using 
combination nanoadjuvants
Although the combination nanoadjuvants induced robust 
immune responses with a prime-boost regimen in young mice, 
vaccines that elicit protection in a single dose are ideal. To 
ascertain the efficacy of a single dose combination 
nanoadjuvant formulation against influenza virus infection, the 
responses of young mice receiving two doses (day 0 and 21) or 
a single dose of the combination nanoadjuvant formulation 
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were compared. Regardless of vaccine regimen, all mice 
received a total of 20 µg HA and 20 µg NP. Serum was 
collected at day 32 post-vaccination and analyzed for the 
presence of anti-HA and anti-NP antibodies (Fig. 2A). The 
young mice developed antibody responses against both HA 
and NP antigens, regardless of regimen.
Mice were challenged intranasally with live A/PR/8/34 at 
day 35, after which their body weight and survival were 
monitored for 14 days. Regardless of administration regimen, 
the young mice maintained body weight post-infection (Fig. 
2B). In addition, the vaccinated young mice demonstrated 
100% survival compared to non-vaccinated, infected control 
mice with approximately 40% survival (Fig. 2C).
Combination nanovaccine protected young mice from IAV 
challenge
After demonstrating that a single dose nanoadjuvant 
formulation induced protection in young mice, the efficacy of 
the single dose combination nanovaccine was compared to 
that induced by inactivated influenza virus (i.e., similar to a 
Fig. 1 Nanoadjuvants enhanced immune response after prime-boost 
vaccination in young mice. (A) Anti-HA total IgG antibody titers 35 days after 
primary immunization. Dotted line represents limit of detection. (B) Virus titers 
assessed three days post-challenge. Numbers below each group indicate 
number of mice with detectable viral load. (C) Body weight monitored for eight 
days post-challenge. Mice were challenge intranasally with 0.5 HAU/mouse. 
Statistical differences in titer were determined using Kruskal-Wallis and Mann-
Whitney tests. Different letters indicate significant differences. n=12. Statistical 
differences in body weight were determined with a repeated measure ANOVA. 
n=6. p ≤ 0.05. Error bars represent standard error of mean.
Fig. 2 Combination nanoadjuvants optimized for single dose regimen in young 
mice. (A) Antibody titer 32 days after immunization with a single dose or two 
dose (day 0 and 21) regimen. Dotted line indicates limit of detection. *indicates 
significant differences determined by Kruskal-Wallis and Mann-Whitney tests. 
(B) Body weight monitored for 14 days post-challenge. Mice were challenge 
intranasally with 0.5 HAU/mouse.  Significant differences between single dose 
(*) or two dose (#) regimens and saline controls at individual time points are 
indicated. Different letters indicate significant differences overall as determined 
with a repeated measure ANOVA. (C) Survival of mice 14 days post-challenge. * 
indicates statistical differences via the log rank Mantel-Cox test. n=7. p ≤ 0.05. 
Error bars represent standard error of mean.
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traditional influenza vaccines as opposed to recombinant 
antigens) and saline controls.
Serum microneutralization titers were measured at 35 days 
post-immunization. While mice immunized with the 
inactivated IAV demonstrated a significant microneutralization 
response, combination nanovaccine-administered mice did not 
have a titer significantly greater than that of saline controls 
(Fig. 3A). However, when the anti-HA total IgG antibody titers 
were measured in BAL fluid three days post-challenge, animals 
immunized with either the combination nanovaccine or 
inactivated IAV had significantly higher anti-HA titers 
compared to saline controls (Fig. 3B).
Mice were challenged 42 days post-immunization and 
monitored for weight loss, virus load in the lungs three days 
post-challenge, and survival. While mice receiving saline lost 
25% of their body weight and were removed from study within 
5-6 days, the combination nanovaccine protected mice from 
challenge (Fig. 3C). Weight loss in mice administered the 
combination nanovaccine and inactivated virus was limited to 
~5-10%, and no significant differences were observed between 
the two groups. In addition, the combination nanovaccine and 
inactivated virus significantly reduced the virus load (i.e., ≥ 
99%) in the lungs of mice post-challenge (Fig. 3D), and 
protected 100% of the mice in contrast to saline controls (Fig. 
Fig. 3 Combination nanovaccine protected young mice from IAV 
challenge. (A) Microneutralization titers 35 days after primary 
immunization. (B) Anti-HA total IgG titer in BAL fluid three days post-
challenge. Dotted line represents limit of detection. (C) Body weight 14 
days post-challenge . (D) Virus titers assessed three days post-challenge. 
(E) Survival 14 days post-challenge. Mice were challenge intranasally 
with 0.5 HAU/mouse. Statistical differences in titer were determined 
using Kruskal-Wallis and Mann-Whitney tests. n=8-16. Statistical 
differences in body weight were determined with a repeated measure 
ANOVA. Statistical differences in survival determined via the log rank 
Mantel-Cox test. Different letters indicate significant differences. n=8. p 
≤ 0.05. Error bars represent standard error of mean.
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3E).
Combination nanoadjuvant formulations for aged mice
Similar to nanoadjuvant optimization in young mice, we 
examined the immune responses of single and two dose 
regimens in aged mice. As expected, antibody production in 
aged mice was lower in comparison to that in young mice. 
While the two dose formulation induced greater anti-HA 
antibody production in aged mice compared to the single dose 
vaccine, both regimens generated similar levels of anti-NP 
antibody (Fig. 4A). 
After virus challenge, the aged mice displayed significantly 
less weight loss post-challenge compared to non-immunized 
controls, regardless of regimen (Fig. 4B). Also, both the single 
dose and two dose regimens induced similar levels of 
protection (~85%) in aged mice (Fig. 4C).
Nanoparticles enhanced activation of dendritic cells isolated from 
aged mice
Following vaccination with the combination nanoadjuvants, we 
observed that aged mice (Fig. 4) had reduced serum antibody 
responses in comparison to young mice (Fig. 2). However, 
despite the absence of demonstrable antibody in aged mice, 
the combination nanovaccine formulation protected against 
virus challenge suggesting that other immune mechanisms 
(e.g., cell-mediated immunity) may be at play. Indeed, cell-
mediated immunity (i.e., CD8+ T cells) has been suggested as a 
better correlate of protection in older adults compared to 
antibody.31 However, it is known that age-related immune 
deficiencies, including poor dendritic cell (DC) activation, often 
result in poor cell-mediated immunity.14 While the ability of 
nanoadjuvants to enhance DC activation in young mice has 
been demonstrated,32, 33 we examined the ability of 
nanoadjuvants to activate DCs isolated from aged mice.
Splenic DCs isolated from aged mice were stimulated with 
the nanoadjuvants for 48 h and the upregulation of 
costimulatory markers was examined via flow cytometry. The 
upregulation of CD86, CD80, and CD40 in conventional DCs 
(CD11c+ MHCII+) was found to be significantly enhanced when 
stimulated with nanoparticles (Fig. 5A). In contrast, we did not 
observe any significant upregulation of the cell surface 
markers when stimulated with micelles, which is consistent 
with our previous findings in young splenic DCs.20 Additionally, 
two sub-populations of conventional DCs were analyzed: 
CD8α+ (Fig. 5B) and CD103+ (Fig. 5C). CD8α+ DCs have been 
shown to efficiently cross-present exogenous antigens to CD8+ 
T cells leading to an effective CTL response.34, 35 The α4βE 
integrin CD103 expressed on DCs also plays an important role 
in the migration of DCs and the induction of T cell-mediated 
responses, especially in mucosal surfaces such as the lung 
epithelium.36 The nanoparticles significantly enhanced the 
expression of co-stimulatory molecules on CD8α+ and CD103+ 
DCs (Fig. 5B & 5C, respectively) while micelles did not activate 
either DC subpopulation.
While secretion of pro-inflammatory cytokines is important 
for the activation of immune responses, they may prove 
detrimental in the already increased inflamed state of older 
adults (i.e., “inflamm-aging”). The supernatants harvested 
from DCs recovered from aged mice were examined for 
secretion of cytokines. The data demonstrated DCs from aged 
mice stimulated with nanoparticles or micelles did not 
significantly increase the secretion of pro-inflammatory 
Fig. 4 Optimization of combination nanoadjuvants in aged mice. (A) Optical 
density of total IgG ELISA 32 days after immunization with a single dose or two 
dose (day 0 and 21) regimen. *indicates significant differences determined by 
Kruskal-Wallis and Mann-Whitney tests. (B) Body weight monitored for 14 days 
post-challenge. Significant differences between single dose (*) or two dose (#) 
regimens and saline controls at individual time points are indicated. No statistical 
significance observed overall. (C) Survival of aged mice 14 days post-challenge. No 
significant differences observed. Mice were challenge intranasally with 0.5 
HAU/mouse. n=7. p ≤ 0.05. Error bars represent standard error of mean.
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cytokines (Fig. 6A & B, respectively). In contrast, LPS (i.e., TLR4 
agonist) significantly increased production of cytokines such as 
IL-1β, IL-6, and TNFα.
Combination nanovaccine protected aged mice from IAV challenge
The nanoadjuvants were shown to stimulate to DCs from aged 
mice (Fig. 5&6), however, we noted that the antibody 
response of aged mice was not robust (Fig. 4). In this regard, 
CDNs have been shown to induce robust and long-lasting 
antibody titers following a single immunization.23 Thus, CDNs 
(i.e., a STING agonist) was included in the combination 
nanoadjuvant formulation in order to improve the immune 
response following administration in aged mice. Due to the 
minimal weight loss observed in control aged mice (Fig. 4), the 
virus dose was increased by ten-fold (5 HAU) to examine 
vaccine efficacy.
Serum was collected from aged mice 35 days post-
immunization and examined for the presence of anti-HA and 
anti-NP antibody titers. While the combination nanovaccine + 
CDN formulation and inactivated IAV induced significant anti-
HA IgG antibody titers, the responses to NP were minimal to 
none (Fig. 7A&B). Although no significant differences were 
observed in microneutralization titers, the combination 
nanovaccine + CDN formulation induced an average titer that 
was an order of magnitude greater than that induced by the 
Fig. 5 Nanoparticles activated innate immune cells from aged mice. CD86, CD80, and CD40 mean fluorescence intensity (MFI) of (A) CD11c+, (B) CD8α+, and (C) CD103+ 
dendritic cells isolated from the spleens of aged mice. Statistical differences determined via Tukey t-test. * indicates significant difference compared to unstimulated 
control. # indicates significant difference compared to sOva. n=3. p ≤ 0.05. Error bars represent standard error of mean.
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inactivated IAV control (Fig. 7C). Clinically, mice administered 
the combination nanovaccine + CDN formulation lost 
approximately 10-15% of their body weight and 60% of the 
mice survived the lethal challenge, as did the aged mice 
receiving the inactivated IAV control (Fig. 7D&E).
Discussion
Other than the use of higher dose vaccines (e.g., Fluzone High-
Dose), the design and development of more effective vaccines 
for older adults is largely unmet. Immunosenescence in aging 
individuals often leads to poor immune responses after 
vaccination,14, 37 and thus, novel vaccines that enhance 
immune responsiveness in elderly are urgently needed. While 
combination nanovaccines based on polyanhydride 
nanoparticles and pentablock copolymer micelles have 
previously shown success against infections with low 
pathogenic H5N1 influenza virus in young animals,21 the 
current work demonstrates the ability of nanovaccines to 
induce protection in both young and aged animals against 
seasonal H1N1 IAV.
Immunosenescence involves age-related immune 
deficiencies in both the innate and adaptive immune 
responses such as poor antigen presentation,38 reduced T cell 
help,39, 40 and low antibody production.37 In this context, 
vaccine formulations composed of multiple adjuvants may 
engage immune signalling/activation pathways differently for 
optimal efficacy. For example, studies have shown elevated 
levels of inflammatory factors including IL-1β, TNF-α, IL-6, IL-17 
in aged animals,41, 42 which are linked to poorer vaccine 
Fig. 6 Nanoadjuvants do not induce pro-inflammatory cytokine secretion from resting splenic DCs recovered from aged mice. Cytokine secretion (presented in red as fold 
change over an unstimulated control) in the supernatant of aged mice splenic DCs stimulated with (A) nanoparticles, (B) micelles, or (C) LPS. Cytokines that are considered 
inflammatory are shaded in pink. An expanded view of the data is presented on the right for clarification. Data was obtained from three independent pools of splenic DCs.
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responses.22 In addition, defects in cytokine production from 
DCs have been highly correlated with poor antibody 
responses.43 While acute and transient inflammation is an 
important part of the defence and clearance of pathogens, 
chronic and persistent inflammation in elderly can be 
detrimental. An aged immune system requires a careful 
balancing of innate immune activation and optimal induction 
of adaptive immune responses. In this work, the polyanhydride 
nanoparticles were found to activate dendritic cells with little 
to no inflammation as represented by reduced pro-
inflammatory cytokine secretion in comparison with a TLR4 
agonist (Fig. 6). In addition, the expression of co-stimulatory 
molecules such as CD80, CD86, CD40 are also known to be 
diminished in aged mice.44 In this work, the nanoparticles 
significantly enhanced upregulation of co-stimulatory 
molecules in conventional, CD8α+, and CD103+ DCs (Fig. 5). 
Indeed, CD8α+ DCs have been shown to efficiently cross-
present exogenous antigens to CD8+ T cells leading to an 
effective CTL response.34, 35 Furthermore, CD103+ DCs play an 
important role in the uptake of antigen at the site of infection 
and delivery of antigen to the draining lymph node for the 
induction of T cell mediated responses, especially at mucosal 
surfaces such as the lung epithelium.45 
In addition to enhanced DC responses, polyanhydride 
Fig. 7 Combination nanovaccine protected aged mice from IAV 
challenge. (A) Anti-HA and (B) anti-NP total IgG antibody titers 
and (C) microneutralization titer 35 days after immunization. 
Dotted line represents limit of detection. (D) Body weight 14 days 
post-challenge. (E) Survival 14 days post-challenge. Mice were 
challenge intranasally with 5 HAU/mouse. Statistical differences in 
titer were determined using Kruskal-Wallis and Mann-Whitney 
tests. Statistical differences in body weight were determined with 
a repeated measure ANOVA. Statistical differences in survival 
determined via the log rank Mantel-Cox test. Different letters 
indicate significant differences. n=8-9. p ≤ 0.05. Error bars 
represent standard error of mean.
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nanoparticles have also been demonstrated to enhance the 
induction of antigen-specific cytotoxic T cells46 and promote 
production of virus neutralizing antibodies.4, 21 Likewise, 
pentablock copolymer micelles provide a matrix within which 
both antigen and nanoparticles are maintained as well as 
promote the rapid and sustained development of high 
antibody titers.19 As a case in point, although animals 
administered the HA and NP in each adjuvant alone generated 
robust antibody titers (Fig. 1), combining the two 
nanoadjuvants (i.e., nanoparticles and micelles) produced the 
greatest mean titer and reduction in viral load in the lungs. 
Thus, we hypothesize that formulations utilizing combination 
adjuvants would effectively activate multiple immune 
pathways and would overcome immune deficits in older adults 
resulting in more efficacious vaccines. 
The ability to formulate a single dose vaccine, especially for 
seasonal IAV vaccines, is ideal for improved patient compliance 
and efficiency of vaccine distribution to a naïve population. 
Previously, polyanhydride nanovaccines have been shown to 
induce elevated antibody titers with suboptimal doses of 
antigen.47 However, the onset of these antibody responses are 
typically delayed due to the slow release kinetics of antigen 
from the particles. In addition, higher doses of antigen are 
often necessary in developing effective vaccines for older 
adults.48, 49 In this work, we hypothesize that a large initial 
bolus of soluble antigen adjuvanted by the pentablock 
copolymer micelles may more effectively initiate the induction 
of an immune response while the sustained release of antigen 
from the nanoparticles promotes the maturation and 
development of immunological memory. In this manner, the 
combination nanovaccine formulated as a single dose resulted 
in similar efficacy as a two dose immunization regimen in both 
young and aged mice (Fig. 2 & 4).
Protection against IAV involves multiple immune pathways, 
especially in older adults, including mucosal immunity, non-
neutralizing antibody, and T cell immunity. Generation of 
mucosal immunity is often important when considering 
respiratory pathogens such as IAV. Indeed, the pulmonary 
tract contains immunoreactive sites enriched with B and T cells 
that may respond quickly upon exposure.50 Our data 
demonstrates that although serum antibody responses were 
diminished, robust titers were observed in the BAL fluid 
suggesting that perhaps some mucosal immunity played a role 
in subsequent protection from challenge (Fig. 3). In this regard, 
intranasal IAV nanovaccines have been shown to induce local 
and systemic immunity resulting in protection against both 
homologous and heterologous IAV challenge.18 Thus, 
vaccination strategies that allow for intranasal administration 
of combination nanovaccines and enhance mucosal immunity 
in older adults may be explored in future studies.
Although anti-HA titers are important, it is known that 
vaccines incorporating multiple antigens, especially conserved 
viral proteins, may be necessary for protection against 
heterologous IAV strains.51, 52 Recently, non-neutralizing 
antibodies in cooperation with antigen-specific CD8+ T cells 
were demonstrated to provide immunity against IAV 
challenge.53, 54 With respect to the data presented in this work, 
the aged mice generated a greater anti-NP antibody response 
compared to their anti-HA antibody response (Fig. 4) 
suggesting that while the combination nanovaccine provided 
protection in both young and aged mice, the mechanisms of 
protection in aged mice may rely on the breadth of the 
immune response (i.e., cell-mediated immunity). 
While outside the scope of this work, it is vital to note that 
recent evidence suggests that T cell responses may correlate 
better to protection against IAV in older adults.31 The T cells 
typically respond to epitopes present on conserved, internal 
viral proteins such as NP.52, 55 As a result, CD8+ T cell responses 
play a central role in enhancing viral clearance55 and greatly 
contribute to providing heterologous protection against 
subsequent infections.52, 55 Therefore, vaccine formulations 
that enhance cell-mediated immune responses towards these 
conserved epitopes would be beneficial for older adults. 
Indeed, polyanhydride nanovaccines have previously been 
demonstrated to enhance cytotoxic T cell responses and 
promote development of immunological memory including 
tissue-resident memory T cells.18, 46 In addition, while the 
combination nanovaccine induced low neutralizing antibody 
titers in young mice, 100% protection was achieved suggesting 
that cellular immune responses may be, in part, responsible 
for protection (Fig. 3). These cellular immune responses 
coupled with the demonstrable antibody response to NP 
antigen in aged mice (Fig. 4) suggest that the combination 
nanovaccine formulation induced cell-mediated immune 
mechanisms of protection to be explored in future studies.
Finally, we hypothesize that the appropriate selection of 
unique nanoadjuvants allows for the induction of robust 
immune responses in aged mice without exacerbating the 
state of inflammation in aged mice resulting in protective 
immunity against influenza virus. Indeed, the combination of 
multiple nanoadjuvants in this work was found to provide 
protection in aged mice against influenza virus as evidenced by 
minimizing weight loss and enhancing survival post-challenge 
relative to saline controls (Fig. 7). We speculate that in 
addition to the benefits previously discussed, the 
polyanhydride nanoparticles provide sustained delivery of 
antigen which may induce cross priming of CD8+ T cells and aid 
in the development of T cell memory. However, this sustained 
delivery of antigen often results in the delayed development of 
antibody responses.56 Therefore, the inclusion of micelles and 
CDNs, which induce high antibody titers early post-
immunization, are beneficial co-adjuvants.19, 20, 23 Finally, the 
micelles may provide a depot of antigens and/or 
nanoadjuvants and encourage delivery of antigen to the 
cytosol.20 These nanoadjuvants used concomitantly set the 
stage for the development of an efficacious single dose 
influenza virus nanovaccine for older adults.
Conclusions
Due to age-related immune deficiencies, the development of 
successful influenza vaccines for older adults is an unmet 
need. In this work, the efficacy of a combination nanovaccine 
based on polyanhydride nanoparticles and pentablock 
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copolymer micelles that contained the IAV HA and NP antigens 
was demonstrated in both young and aged mice. The 
combination of two nanoadjuvants was shown to induce 
elevated antibody titers resulting in reduced viral load and 
100% protection in young mice. More significantly, the 
nanoparticles enhanced activation of DCs from aged mice, 
which may promote cell-mediated immune responses. 
Together, these data provide evidence that a combination 
nanovaccine platform based on pentablock copolymer micelles 
and polyanhydride nanoparticles is a promising technology to 
rationally design influenza vaccines for older adults.
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